ClinicalTrials.gg
Active, not recruitingNCT05503264CieloUpdated Oct 8, 2026

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis

A Phase 3 interventional study of Satralizumab and Placebo in NMDAR Autoimmune Encephalitis and LGI1 Autoimmune Encephalitis, sponsored by Hoffmann-La Roche. Active, not recruiting at 56 sites in 15 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Updated Oct 8, 2026No longer in Singapore and Spain21 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.

02

Conditions studied

  • NMDAR Autoimmune Encephalitis
  • LGI1 Autoimmune Encephalitis
03

In context

Autoimmune Diseases of the Nervous System

123 studies on the registry are indexed under Autoimmune Diseases of the Nervous System; 59 are open to participants now.

This study's enrollment of 122 is above the median of 40 across 63 interventional studies indexed under Autoimmune Diseases of the Nervous System.

Browse Autoimmune Diseases of the Nervous System studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Reasonable exclusion of tumor or before baseline visit (randomization)
  • Onset of AIE symptoms ≤ 9 months before randomization
  • Meet the definition of "New Onset" or "Incomplete Responder" AIE
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use adequate during the treatment period and for at least 3 months after the final dose of satralizumab or placebo
  • For participants enrolled in the extended China enrollment phase at China's sites: participants who are current residents of mainland China, Hong Kong, or Taiwan, and of Chinese ancestry

NMDAR AIE Cohort:

  • Age ≥ 12 years
  • Diagnosis of probable or definite NMDAR encephalitis

LGI1 AIE Cohort

  • Age ≥ 18 years
  • Diagnosis of LGI1 encephalitis

Exclusion criteria

Exclusion Criteria:

  • Any untreated teratoma or thymoma at baseline visit (randomization)
  • History of carcinoma or , unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening
  • For participants with NMDAR AIE, history of negative anti-NMDAR antibody in cerebrospinal fluid (CSF) using a cell-based assay within 9 months of symptom onset
  • Historically known positivity to an intracellular antigen with high cancer association or glutamate decarboxylase 65 (GAD-65)
  • Historically known positivity to any cell surface neuronal antibodies other than NMDAR and LGI1, in the absence of NMDAR and LGI1 antibody positivity
  • Confirmed paraneoplastic encephalitis
  • Confirmed central nervous system (CNS) or peripheral nervous system (PNS) demyelinating disease
  • Alternative causes of associated symptoms
  • History of herpes simplex virus encephalitis in the previous 24 weeks
  • Any previous/concurrent treatment with interleukin-6 (IL-6) inhibitory therapy (e.g., tocilizumab), alemtuzumab, total body irradiation, or bone marrow transplantation
  • Any previous treatment with anti-cluster of differentiation 19 antibody (CD19 antibody), complement inhibitors, neonatal Fc receptor antagonists, anti-B-lymphocyte stimulator monoclonal antibody
  • Any previous treatment with T-cell depleting therapies, cladribine, or mitoxantrone
  • Treatment with oral cyclophosphamide within 1 year prior to baseline
  • Treatment with any drug (including bortezomib) within 24 weeks prior to screening
  • Concurrent use of more than one therapy (IST) as background therapy
  • to all of the following rescue treatments: rituximab, intravenous immunoglobulin (IVIG), high-dose , or intravenous (IV) cyclophosphamide
  • Any surgical procedure, except laparoscopic surgery or minor surgeries within 4 weeks prior to baseline, excluding surgery for thymoma or teratoma removal
  • Planned surgical procedure during the study
  • Evidence of progressive multifocal leukoencephalopathy
  • Evidence of serious uncontrolled concomitant diseases
  • Congenital or acquired immunodeficiency, including (HIV) infection
  • Active or presence of recurrent bacterial, viral, fungal, mycobacterial infection, or other infection
  • Infection requiring hospitalization or treatment with IV anti-infective agents within 4 weeks prior to baseline visit
  • Positive (HBV) and (HCV) test at screening
  • Evidence of latent or active tuberculosis (TB)
  • History of drug or alcohol abuse within 1 year prior to baseline
  • History of diverticulitis or concurrent severe gastrointestinal (GI) disorders that, in the investigator's opinion, may lead to increased risk of complications such as GI perforation
  • Receipt of live or within 6 weeks prior to baseline visit
  • History of blood donation (1 unit or more), plasma donation or donation within 90 days prior to screening
  • History of severe allergic reaction to a biologic agent
  • History of suicide attempt within 3 years prior to screening except if this is clearly associated with and occurs during the acute phase of LGI-1 or NMDAR encephalitis
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes safe participation in and completion of the study
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of study drug
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    NMDAR Autoimmune Encephalitis (AIE) Cohort

    Adults and adolescents with definite or probable NMDAR encephalitis will receive satralizumab as per the schedule specified in the protocol. As of Protocol Version 6, participants in Part 1 will transition to Part 2 at the time of primary analysis or at Week 52, whichever occurs first.

    Drug: Satralizumab

  • Experimental
    LGI1 AIE Cohort

    Adults with LGI1 encephalitis as per the schedule specified in the protocol.

    Drug: Satralizumab

  • Placebo comparator
    NMDAR AIE Placebo Cohort

    Adults and adolescents with definite or probable NMDAR encephalitis will receive satralizumab placebo as per the schedule specified in the protocol. As of Protocol Version 6, participants in Part 1 will transition to Part 2 at the time of primary analysis or at Week 52, whichever occurs first.

    Other: Placebo

  • Placebo comparator
    LGI1 AIE Placebo Cohort

    Adults with LGI1 encephalitis will receive satralizumab placebo as per the schedule specified in the protocol.

    Other: Placebo

Interventions

  • In Part 1, study drug will be administered after all other study-related procedures have been performed at a site visit at Weeks 0, 2, 4, and every 4 weeks (Q4W) thereafter. Participants will receive satralizumab according to body weight, administered as subcutaneous (SC) injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit. In Part 2, participants will be asked to choose from one of the following options: Option 1: continue on randomized, double-blind study drug; Option 2: start open-label satralizumab based on body weight; Option 3: stop study treatment and continue follow-up assessments. As of Protocol Version 6, participants in the NMDAR cohort who chose Option 1 will transition to either Option 2 or Option 3 at the time of the primary analysis.

    Also known as: Enspryng; RO5333787

  • OtherPlacebo

    Satralizumab placebo prefilled syringe (PFS) is identical in composition to satralizumab PFS, but does not contain the satralizumab active ingredient and will be identical in appearance and packaging to satralizumab. A PFS (assembled with an needle safety device \[NSD\] and extended finger flange) filled with 0.5 milliliters (mL) of solution, corresponding to 60 milligrams (mg) satralizumab, may be used in Part 2 once it becomes available at the study site.

06

What researchers measure

Primary outcomes

  1. Part 1: Proportion of Participants in NMDAR AIE Cohort With Modified Rankin Scale (mRS) Score Improvement ≥ 1 From Baseline and no Use of Rescue Therapy at Week 24

    Time frame: Baseline up to Week 24

  2. Part 1: Proportion of Participants in LGI1 AIE Cohort With mRS Score Improvement ≥ 1 From Baseline and no Use of Rescue Therapy at Week 52

    Time frame: Baseline up to Week 52

  3. Part 2: Percentage of Participants With Adverse Events (AEs)

    Time frame: From Week 52 up to 4 years

Secondary outcomes

  1. Part 1 (NMDAR AIE Cohort and LGI1 Cohort): Time to mRS Score Improvement ≥ 1 From Baseline Without Use of Rescue Therapy

    Time frame: Baseline up to Week 52

  2. Part 1 (NMDAR AIE Cohort and LGI1 AIE Cohort): Time to Rescue Therapy

    Time frame: Baseline up to Week 52

  3. Part 1 (NMDAR AIE Cohort and LGI1 AIE Cohort): Proportion of Participants With Sustained Seizure Cessation at Week 24

    Sustained seizure cessation is defined as 4 consecutive weeks of no seizures maintained until Week 24 and no use of rescue therapy.

    Time frame: Baseline up to Week 24

  4. Part 1 (NMDAR AIE Cohort): Change in Clinical Assessment Scale in Autoimmune Encephalitis (CASE) Score From Baseline at Week 24

    Time frame: Baseline up to Week 24

  5. Part 1 (LGI1 AIE Cohort): Change in CASE Score From Baseline at Week 52

    Time frame: Baseline up to Week 52

  6. Part 1 (NMDAR AIE Cohort): Montreal Overall Cognitive Assessment (MOCA) Total Score at Week 24

    Time frame: Baseline up to Week 24

  7. Part 1 (LGI1 AIE Cohort): MOCA Total Score at Week 52

    Time frame: Baseline up to Week 52

  8. Part 1 (LGI1 AIE Cohort): Rey Auditory Verbal Learning Test (RAVLT) Score at Week 52

    Time frame: Baseline up to Week 52

  9. Part 1 (NMDAR AIE Cohort): mRS Score at Week 24 (as Measured on a 7-point Scale)

    Time frame: Baseline up to Week 24

  10. Part 1: Percentage of Participants With AEs

    Severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE V5.0)

    Time frame: Baseline up to Week 52

  11. Parts 1 and 2: Change from Baseline in Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.

    Time frame: Baseline up to 5 years

07

Study locations

56 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 50 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2022
First posted
Aug 16, 2022
StartActual
Sep 27, 2022
Primary completionEst.
Dec 16, 2026
CompletionEst.
Dec 14, 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites removed; no longer in Singapore and Spain
Show 21 removed
  • UC San Diego · La Jolla, United States
  • Children's Healthcare of Atlanta Center for Advanced Pediatrics · Atlanta, United States
  • University of Maryland Medical Center · Baltimore, United States
  • Johns Hopkins Hospital · Baltimore, United States
  • Duke University Medical Center · Durham, United States
  • University of Texas at Houston · Houston, United States
  • CHRU - Hôpital Bretonneau · Tours, France
  • IRCCS Ospedale San Raffaele · Milan, Italy
  • Fondazione IRCCS Istituto Neurologico Carlo Besta · Milan, Italy
  • Fukuoka University Hospital · Fukuoka, Japan
  • Hyogo prefectural Kobe Children's Hospital · Hyogoken, Japan
  • Kagoshima City Hospital · Kagoshima, Japan
  • Kindai University Hospital · Osaka, Japan
  • Ageo Central General Hospital · Saitama, Japan
  • Juntendo University Hospital · Tokyo, Japan
  • Instytut Psychiatrii i Neurologii II Klinika Neurologiczna · Warsaw, Poland
  • National University Hospital (NUH) · Singapore, Singapore
  • National Neuroscience Institute · Singapore, Singapore
  • Hospital Alvaro Cunqueiro · Vigo, Spain
  • Hospital General Universitario Gregorio Marañon · Madrid, Spain
  • Hospital Regional Universitario de Malaga ? Hospital General · Málaga, Spain
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    21 sites removed; no longer in Singapore and Spain
    Show 21 removed
    • UC San Diego · La Jolla, United States
    • Children's Healthcare of Atlanta Center for Advanced Pediatrics · Atlanta, United States
    • University of Maryland Medical Center · Baltimore, United States
    • Johns Hopkins Hospital · Baltimore, United States
    • Duke University Medical Center · Durham, United States
    • University of Texas at Houston · Houston, United States
    • CHRU - Hôpital Bretonneau · Tours, France
    • IRCCS Ospedale San Raffaele · Milan, Italy
    • Fondazione IRCCS Istituto Neurologico Carlo Besta · Milan, Italy
    • Fukuoka University Hospital · Fukuoka, Japan
    • Hyogo prefectural Kobe Children's Hospital · Hyogoken, Japan
    • Kagoshima City Hospital · Kagoshima, Japan
    • Kindai University Hospital · Osaka, Japan
    • Ageo Central General Hospital · Saitama, Japan
    • Juntendo University Hospital · Tokyo, Japan
    • Instytut Psychiatrii i Neurologii II Klinika Neurologiczna · Warsaw, Poland
    • National University Hospital (NUH) · Singapore, Singapore
    • National Neuroscience Institute · Singapore, Singapore
    • Hospital Alvaro Cunqueiro · Vigo, Spain
    • Hospital General Universitario Gregorio Marañon · Madrid, Spain
    • Hospital Regional Universitario de Malaga ? Hospital General · Málaga, Spain
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05503264
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 16, 2022
Start date
Sep 27, 2022
Primary completion
Dec 16, 2026 (estimated)
Completion
Dec 14, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Satralizumab

Start the discussion